15 To 23 Amino Acid Residues In Defined Sequence Patents (Class 530/326)
-
Publication number: 20150071958Abstract: The invention relates to methods and compositions for treating or inhibiting infection of Clostridium difficile. The methods and compositions generate rapid immune responses that inhibit future infection, and/or neutralize the toxicity caused by C. difficile infection.Type: ApplicationFiled: November 29, 2012Publication date: March 12, 2015Applicant: Board of Trustees of Michigan State UniversityInventors: Andrea Amalfitano, Sergey Seregin
-
Publication number: 20150072895Abstract: The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins that are particularly advantageous for quantifying the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.Type: ApplicationFiled: November 17, 2014Publication date: March 12, 2015Inventors: David B. KRIZMAN, Wei-Li LIAO, Sheeno THYPARAMBIL, Todd HEMBROUGH
-
Publication number: 20150072933Abstract: The present invention relates to novel peptide sequences, compositions and methods for controlling fish reproduction. More particularly, the invention provides novel Neurokinin B peptides NKF and NKB and analogues thereof that regulate reproduction in fish. The invention further provides preprohormone thereof comprising at least one of a first peptide fragment of the amino acid sequence X1-X2-X3-X4-X5-X6-Asp7-X8-Phe9-Val10-X11-Leu12-Met13 and a second peptide fragment of the amino acid sequence of Glu1-Met2-His3-Asp4-Ile5-Phe6-Val7-Gly8-Leu9-Met10 and variants thereof, nucleic acid sequences and novel fish NKB receptors.Type: ApplicationFiled: August 1, 2012Publication date: March 12, 2015Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Berta Levavi-Sivan, Chaim Gilon
-
Patent number: 8975384Abstract: The present invention provides a tag peptide comprising an amino acid sequence represented by the following formula (I): X1-Tyr-X2-Gly-Gln-X3??(I) (wherein X1, X2 and X3 are the same or different and each represent any amino acid residue) and an antibody against the tag peptide. By combined use of the tag peptide and antibody of the present invention, a system that enables proteins expressed from cloned genes to be highly purified in an inexpensive and easy manner can be established.Type: GrantFiled: December 18, 2008Date of Patent: March 10, 2015Assignee: Osaka UniversityInventor: Junichi Takagi
-
Patent number: 8975371Abstract: The present invention relates to novel melanoma antigen peptides and specific T lymphocytes directed to said peptides and the use thereof for treating melanoma.Type: GrantFiled: November 21, 2013Date of Patent: March 10, 2015Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Nantes, Chu NantesInventors: Nathalie Labarriere, Agnes Moreau-Aubry, Yann Godet
-
Patent number: 8975231Abstract: A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2, as do endogenous forms of BBP, and sequence conservation between species results in a variety of useful BBP compositions. BBP increases the over-all osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis.Type: GrantFiled: June 1, 2012Date of Patent: March 10, 2015Assignees: The Regents of the University of California, The United States of America represented by the Department of Veterans AffairsInventors: Samuel S. Murray, Elsa J. Brochmann-Murray, Jeffrey Wang, Keyvan Behnam
-
Patent number: 8975086Abstract: The present invention provides therapeutic agents and methods for treating cancer using the polypeptides composed of an amino acid sequence which includes a polypeptide fragment of DEPDC1. The polypeptides of the present invention can be introduced into cancer cells by modifying the polypeptides with transfection agents such as poly-arginine. Furthermore, the present invention provides methods of screening for therapeutic agents or compounds useful in inhibition of the DEPDC1/ZN-F224 complex formation or the treatment of cancer. The present invention also provides siRNAs targeting the ZNF224 gene, which are suggested to be useful in the treatment of bladder cancer.Type: GrantFiled: August 21, 2009Date of Patent: March 10, 2015Assignee: OncoTherapy Science, Inc.Inventors: Yusuke Nakamura, Toyomasa Katagiri, Akira Togashi
-
Publication number: 20150065385Abstract: The invention provides an isolated peptide comprising a crotonylation site, a Kcr-specific affinity reagent that specifically binds to the peptide, and a method for detecting protein crotonylation in a sample using the reagent.Type: ApplicationFiled: November 3, 2014Publication date: March 5, 2015Applicant: PTM BIOLABS, INC.Inventors: YINGMING ZHAO, JEONG SOO YANG, HAO LUO, ZHONGYI CHENG
-
Publication number: 20150065373Abstract: A novel method that enables prostate cancer testing that is noninvasive and more accurate than conventional methods is disclosed. The present inventors intensively analyzed urine samples from prostate cancer patients, and non-cancer subjects, who are free of prostate cancer, and, as a result, newly discovered urinary peptides that can be used as indicators in prostate cancer testing. Use of these urinary peptides as indicators enables various prostate cancer-related tests including detection of prostate cancer, discrimination between prostate cancer and benign prostatic hyperplasia, monitoring of a therapeutic effect of prostate cancer therapy and monitoring of postoperative recurrence.Type: ApplicationFiled: March 28, 2013Publication date: March 5, 2015Applicant: KYOTO UNIVERSITYInventors: Kenji Nakayama, Kazuharu Shimizu, Jun Utsumi, Takahiro Inoue, Osamu Ogawa
-
Publication number: 20150065414Abstract: The present invention provides modified TLR2 ligands useful for modulating inflammatory responses. In particular, the ligands comprise (a) a fatty acid di- or tri-linoleate and (b) a GM1-binding peptide. The linoleate provides the anti-inflammtory function, while the GM1-binding peptide facilitates endocytosis.Type: ApplicationFiled: August 30, 2012Publication date: March 5, 2015Applicant: UTI LIMITED PARTNERSHIPInventors: Elizabeth M. Long, Stephen M. Robbins, Paul Kubes, Ela Kolaczkowska
-
Publication number: 20150065424Abstract: The invention relates to composition comprising a pharmaceutically effective amount of one or more functional vasoactive intestinal peptide (VIP) fragments, and the use of those compositions in the treatment of fibrosis, hypertension and other disorder.Type: ApplicationFiled: November 17, 2014Publication date: March 5, 2015Applicant: VECTUS BIOSYSTEMS LIMITEDInventor: Karen Annette Duggan
-
Publication number: 20150064726Abstract: A method of bioassay for the quantification of peptide fragments relevant to neurodegenerative conditions comprising a neo-epitope formed by cleavage of a Tau protein by a secretase such as ADAM10 comprises contacting a blood derived sample with an antibody specific for the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. Neo-epitope containing peptide levels are found to be inversely correlated to cognitive function.Type: ApplicationFiled: July 4, 2012Publication date: March 5, 2015Applicant: Nordic Biosciences A/SInventors: Natasha Barascuk Michaelsen, Morten Karsdal, Kim Henriksen
-
Publication number: 20150065435Abstract: The present invention provides reagents and methods for treating dental disease.Type: ApplicationFiled: May 25, 2012Publication date: March 5, 2015Applicant: University of Washington through its Center for CommercializationInventors: Mehmet Sarikaya, Martha Somerman, Candan Tamerler-Behar, Hanson Fong, Hai Zhang, Mustafa Gungormus
-
Publication number: 20150065384Abstract: The present invention provides nucleic acids and peptides, and methods of using the nucleic acids and peptides to identify subjects at risk for a TDP-43 proteinopathy. The invention also provides for an array comprising the nucleic acids and peptides of the invention.Type: ApplicationFiled: October 14, 2014Publication date: March 5, 2015Inventors: Nigel J. Cairns, Robert H. Baloh, Alan Pestronk, Michael A. Gitcho, Alison M. Goate
-
Publication number: 20150065367Abstract: The current invention concerns the identification of B-cell epitopes (as linear peptides) from human polyoma virus proteins and their use in an immune diagnostic assay.Type: ApplicationFiled: December 11, 2012Publication date: March 5, 2015Inventor: Lieven Jozef Stuyver
-
Patent number: 8969515Abstract: The proposed pharmaceutical compositions and methods connected thereto relate to the field of biotechnology and medicine, in particular to pharmaceutical compositions having an antiproliferative activity, and to a method of treating oncologic diseases, which includes introducing the aforementioned chimerical peptide into a mammal requiring such treatment. The object of the proposed compositions and methods is the development of a preparation that effectively penetrates the target cells and has a high cytostatic and cytotoxic action.Type: GrantFiled: May 20, 2011Date of Patent: March 3, 2015Assignee: OOO “MetaMax”Inventor: Vladimir Konstantinovich Bojenko
-
Patent number: 8969514Abstract: This invention also provides a method to prevent, control, and treat a lipid metabolism disorder, a billary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodieasterases.Type: GrantFiled: December 3, 2009Date of Patent: March 3, 2015Assignee: Synergy Pharmaceuticals, Inc.Inventor: Kunwar Shailubhai
-
Patent number: 8969296Abstract: The present invention relates to a GFP-CAP peptide having an amino acid sequence derived from TGF-?1 (transforming growth factor-?1) and a cell adhesion sequence, wherein the amino acid sequence derived from TGF-?1 consists of the amino acid sequence of SEQ ID NO:1 and the TGFP-CAP peptide is represented by the following formula I: Ile-Trp-Ser-Leu-Asp-Thr-Gln-Tyr-Cell adhesion sequence (I). The TGFP-CAP peptide of the present invention exhibits excellent anti-angiogenic activity. In addition, the TGFP-CAP peptide of the present invention prevents effectively melanin generation in skin to have skin whitening effects. The present peptide shows much higher stability and permeability to skin than natural-occurring TGF-?1. Such plausible activities and safety of the present peptide enable advantageously to application to drugs, quasi-drugs and cosmetics.Type: GrantFiled: September 12, 2007Date of Patent: March 3, 2015Assignee: Caregen Co., LtdInventors: Yong-Ji Chung, Young Deug Kim, Eun Mi Kim, Jun Young Choi, Jin Seuk Kim, Sang Su Song, Kyoung Mi Cho
-
Patent number: 8969311Abstract: A novel polypeptide which has an excellent angiogenesis-inducing activity and an excellent antibacterial activity, and a novel angiogenesis-inducing agent which contains the polypeptide as an effective ingredient or a novel agent for treating a wound(s) which contains the polypeptide as an effective ingredient are disclosed. The polypeptide of the present invention is a polypeptide whose amino acid sequence is shown in any one of SEQ ID NOs:1 to 6, 8 and 10. The angiogenesis-inducing agent which contains the polypeptide of the present invention as an effective ingredient is useful for the prevention, amelioration or treatment of a disease such as a burns, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliteran.Type: GrantFiled: May 25, 2010Date of Patent: March 3, 2015Assignee: AnGes MG, Inc.Inventors: Takefumi Gemba, Hideki Tomioka, Nao Tamura, Ryoko Sata, Akito Maeda, Akiko Tenma, Toshihide Kanamori, Yoshimi Saito, Shintaro Komaba, Ryuichi Morishita
-
Patent number: 8969252Abstract: The present invention includes methods for producing magnetic nanocrystals by using a biological molecule that has been modified to possess an amino acid oligomer that is capable of specific binding to a magnetic material.Type: GrantFiled: April 7, 2011Date of Patent: March 3, 2015Assignee: Board of Regents, University of Texas SystemInventors: Angela M. Belcher, Brian D. Reiss, Chuanbin Mao, Daniel J. Solis
-
Publication number: 20150057217Abstract: The present invention relates to amphiphilic peptides having antibacterial and/or antitumor activity, and to therapeutic and non-therapeutic compositions comprising these peptides. The peptides are of structural formula I or II shown below wherein A1, v, A2, w, A3, x, y, A4, z, R1, R2 and R3 are as defined in the application; or a salt thereof. The invention further relates to use of the peptides as antibacterial agents, or antitumor agents, including the medical use of the peptide in treating infection and/or cancer, as well as their use as preservatives and antibacterial agents in other products, including personal care products such as skin topical treatments, cleansers, mouth washes, toothpastes, shampoo, body lotions and creams etc.Type: ApplicationFiled: March 11, 2014Publication date: February 26, 2015Inventors: Jian R. LU, Xiubo ZHAO, Fang PAN, Mohammed YASEEN
-
Publication number: 20150057430Abstract: The present invention relates to the use of an antagonist of kisspeptin in the manufacture of a medicament for the treatment of a condition induced and/or worsened by kisspeptin activity in an individual. The invention also provides certain defined peptide molecules, which may act as an antagonist of kisspeptin, which are of use in treating a condition induced and/or worsened by kisspeptin activity in an individual. In addition, the invention provides methods of identifying and/or using antagonists of kisspeptin and/or the defined peptides, and pharmaceutical compositions thereof.Type: ApplicationFiled: August 26, 2014Publication date: February 26, 2015Inventors: Robert Peter Millar, Antonia Kathryn Roseweir
-
Publication number: 20150057431Abstract: The present invention provides methods of treating (including preventing) a disease or condition associated with abnormal angiogenesis in a subject include administering a therapeutically effective amount of an AA targeting compound of the invention to the subject. The AA targeting compounds comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody.Type: ApplicationFiled: October 31, 2014Publication date: February 26, 2015Inventors: Curt William BRADSHAW, Abhijit Suresh BHAT, Jing-Yu LAI, Venkata R. DOPPALAPUDI, Dingguo LIU
-
Patent number: 8962569Abstract: Provided herein is tumor suppression composition and methods of making and using the same.Type: GrantFiled: May 25, 2011Date of Patent: February 24, 2015Assignees: The Regeants of the University of California, The United States of America as Represented by the Department of Veterans AffairsInventors: Samuel S. Murray, Elsa J. Murray, Jeffrey C. Wang
-
Patent number: 8961986Abstract: There is provided a method for selecting a tolerogenic peptide by selecting a peptide which is capable of binding to an MHC class I or II molecule without further processing. There is also provided a peptide selected by such a method and its use in a pharmaceutical composition and a method to treat and/or prevent a disease. The present invention also relates to a composition which comprises the following myelin basic protein peptides: MBP 30-44; MBP 83-99; MBP 131-145; and MBP 140-154. The composition may be used to treat a disease, in particular multiple sclerosis and/or optical neuritis and the invention also relates to such uses and methods.Type: GrantFiled: December 6, 2012Date of Patent: February 24, 2015Assignee: Apitope Technology (Bristol) LimitedInventors: David Wraith, Heather Barbara Streeter
-
Patent number: 8961989Abstract: Methods for producing an immune response to Mycobacterium tuberculosis (Mtb) are disclosed herein. In several examples, the immune response is a protective immune response. In additional embodiments, methods are disclosed for inhibiting an infection with Mtb, preventing an infection with Mtb, or treating an infection with Mtb. Pharmaceutical compositions for the inhibition, prevention and/or treatment of tuberculosis are also disclosed.Type: GrantFiled: November 19, 2010Date of Patent: February 24, 2015Assignees: Oregon Health & Science University, The United States of America as represented by the Department of Veteran AffairsInventors: David M. Lewinsohn, Deborah A. Lewinsohn
-
Patent number: 8961971Abstract: This invention relates to bispecific antibodies having combinations of linker and hinge sequences to create linker-hinge interface domains with biological significance. Such linker-hinge interface domains covalently join two molecules, maintain the biological activities of linked molecules (target binding), stabilize the biological characteristics of new molecule (solubility and 4° C. stability), maintain the chemical, biochemical and physical properties (cytotoxicity) of the linked molecules, and modulate the biological characteristics of the linked molecules (activating T-lymphocytes without significant sign of proliferations). Both linker (GGGGS) and hinge (CPPCP) sequences are required to establish functional linker-hinge interface domains as deletion of any of the component resulted in significant lost of T-lymphocyte mediated activity.Type: GrantFiled: December 19, 2012Date of Patent: February 24, 2015Assignees: Development Center for Biotechnology, DCB-USA LLCInventors: Yu-Shen Hsu, Show-Shan Sheu, Ming-I Chang, Ming-Chuan Chang, Ta-Tung Yuan
-
Patent number: 8962570Abstract: A method is provided for treatment of a condition mediated by Nox2 in a patient. The method comprises administering to the patient by inhalation a polypeptide as described herein, able to inhibit superoxide production by Nox2. Conditions treatable in this manner include, without limitation, one or more of: right ventricular hypertrophy; pulmonary hypertension; acute lung injury; obstructive sleep apnea; ischemia/reperfusion injury in the lung; pulmonary fibrosis; an obstructive lung disorder such as Chronic Obstructive Pulmonary Disease (COPD), asthma, cystic fibrosis and emphysema; and atherosclerosis.Type: GrantFiled: May 17, 2012Date of Patent: February 24, 2015Assignee: University of Pittsburgh—of the Commonwealth System of Higher EducationInventor: Patrick J. Pagano
-
Publication number: 20150051093Abstract: The invention provides an isolated peptide comprising a lysine 3-hydroxybutyrylation site, a lysine 3-hydroxybutyrylation specific affinity reagent that specifically binds to the peptide, and a method for detecting protein lysine 3-hydroxybutyrylation in a sample using the reagent.Type: ApplicationFiled: August 18, 2014Publication date: February 19, 2015Applicant: PTM Biolabs, Inc.Inventors: Yingming Zhao, Zhongyu Xie
-
Publication number: 20150051153Abstract: An environmentally sensitive membrane binding polypeptide, pH (low)-sensitive membrane peptide (pHLIP) has improved insertion kinetics balanced with solubility to selectively target acidic tissues.Type: ApplicationFiled: July 13, 2011Publication date: February 19, 2015Inventors: Yana K. Reshetnyak, Oleg A. Andreev, Donald M. Engelman
-
Patent number: 8957030Abstract: The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2 a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.Type: GrantFiled: February 27, 2013Date of Patent: February 17, 2015Assignees: Cornell Research Foundation, Inc., Institute de Recherches Cliniques de MontrealInventors: Hazel H. Szeto, Peter W. Schiller, Kesheng Zhao
-
Patent number: 8956622Abstract: The present invention concern a peptidic antagonist of class III semaphorins/neuropilins complexes comprising an amino acid sequence, which is derived from the transmembrane domain of a protein selected in the group consisting of neuropilin-1, neuropilin-2, plexin-A1, plexin-A2, plexin-A3, plexin-A4, Nr-CAM, L1-CAM, integrin Beta 1 and integrin beta 2, and including at least a GxxxG motif, eventually fused to an heterologous sequence; a nucleic acid encoding for said peptidic antagonist, a pharmaceutical composition comprising such a peptidic antagonist or a nucleic acid encoding thereof and uses thereof.Type: GrantFiled: June 28, 2006Date of Patent: February 17, 2015Assignee: INSERM—Institut National de la Sante et de la Recherche MedicaleInventors: Dominique Bagnard, Lise Roth, Cécile Nasarre, Pierre Hubert, Sylvie Dirrig-Grosch, Gerard Cremel, Dominique Aunis
-
Patent number: 8956878Abstract: The present application is directed to a peptides comprising an a-helix forming-amino acid sequence that binds a heat shock protein. Also included is a polypeptide comprising (a) a first peptide portion that comprises an ?-helix-forming amino acid sequence that binds a heat shock protein; and (b) at least one second peptide portion comprising an antigenic amino acid sequence and/or an a-helix-stabilizing amino acid sequence that increases the interaction of the first peptide portion with the heat shock protein. The present application also includes compositions comprising the peptides and/or polypeptides of present application and uses of the peptides and/or polypeptides of the present application for fractionating substances relevant for discovery, research or clinical analysis from a biological sample and as therapeutics.Type: GrantFiled: March 21, 2012Date of Patent: February 17, 2015Assignees: Atlantic Cancer Research Institute, New England Peptide, Inc.Inventors: Steven Gareth Griffiths, Scott Edwin Lewis
-
Patent number: 8957022Abstract: The present invention provides a multimeric form of a Tie 2 binding peptide monomer, wherein the multimeric form has Tie 2 agonist activity. The multimeric form, preferably a tetramer, stimulates angiogenesis and promotes wound healing. The present invention also features pharmaceutical compositions comprising the multimeric Tie 2 agonists, including those suitable for topical or systemic administration. Methods of using the multimeric Tie 2 agonists of the invention for stimulating angiogenesis and for promoting healing of wounds, such as diabetic ulcers or skin grafts, are also provided.Type: GrantFiled: October 26, 2007Date of Patent: February 17, 2015Assignee: Sunnybrook Health Sciences CentreInventors: Paul Van Slyke, Daniel Dumont
-
Patent number: 8957026Abstract: The invention relates to ?-catenin targeting peptides comprising an ?-helical segment that are optionally stapled or stitched, and pharmaceutical compositions thereof. Uses of the inventive ?-catenin targeting polypeptides including methods for treatment of disease, such as diseases associated with aberrant Wnt signaling, including cancer, are also provided.Type: GrantFiled: September 22, 2011Date of Patent: February 17, 2015Assignee: President and Fellows of Harvard CollegeInventors: Gregory L. Verdine, Tom N. Grossmann, Tsung-Han Johannes Yeh
-
Patent number: 8957185Abstract: Peptides from the MUC1 cytoplasmic domain and methods of use therefor are described. These peptides can inhibit MUC1 oligomerization, thereby preventing tumor cell growth, inducing tumor cell apoptosis and necrosis of tumor tissue in vivo.Type: GrantFiled: February 24, 2012Date of Patent: February 17, 2015Assignees: Dana-Farber Cancer Institute, Inc., Genus Oncology, LLCInventors: Donald W. Kufe, Surender Kharbanda
-
Publication number: 20150044701Abstract: This invention provides a peptide that comprises an amino acid sequence consisting of 14 to 18 amino acid residues represented by Formula (I) and is capable of binding to human IgA: (SEQ?ID?NO:?1) H-(X1)-V-C-L-S-Y-R-(X2)-(X3)-G-(X4)-P-(X5)-C- (X6)-(X7)-(X8)(I) wherein each X is independently selected from among the following: X1 represents a Gln residue or a Met residue; X2 and X3 each independently represent an arbitrary amino acid residue other than Cys or either or both thereof are deleted; X4 represents an Arg residue or a Gln residue; X5 represents a Val residue or a Thr residue; X6 represents a Phe residue or a Tyr residue; X7 represents a Ser residue or is null; and X8 represents a Leu residue, a Thr residue, or is null, provided that, when X1 represents a Met residue, X7 represents a Ser residue or is null, and X8 is null. The invention also provides a method for purifying or analyzing human IgA using such peptide.Type: ApplicationFiled: November 29, 2012Publication date: February 12, 2015Applicants: Kagoshima University, Otsuka Chemical Co., Ltd.Inventors: Yuji Ito, Osamu Ito, Shinji Oozono, Hiroyuki Ishitobi
-
Publication number: 20150045506Abstract: A method for producing a polypeptide, includes at least one native ligation step using a peptide functionalized with a selenium group. The selenium peptides and compounds are also described.Type: ApplicationFiled: March 18, 2013Publication date: February 12, 2015Applicants: UNIVERSITE LILLE 2 DROIT ET SANTE, INSTITUT PASTEUR DE LILLEInventors: Oleg Melnyk, Laurent Raibaut, Nathalie Ollivier
-
Publication number: 20150045304Abstract: The invention relates to peptides including DEDE(SSD)nDEG indicated by SEQ NO. 1, RRRDEDE(SSD)nDEG indicated by SEQ No. 2, RRRGDEDE(SSD)nDEG indicated by SEQ No. 3, and LKKLKKLDEDE(SSD)nDEG indicated by SEQ NO. 4, wherein n is an integer from 2 to 20. The invention also relates to phosphorylating these peptides at multiple amino acid sites by employing casein kinases. These phosphorylated peptides may be used in various applications such as forming mineralized collagen fibrils and biometic composites for use in tissue repair and regeneration.Type: ApplicationFiled: November 13, 2013Publication date: February 12, 2015Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: ELIA BENIASH, CHARLES S. SFEIR
-
Publication number: 20150045291Abstract: The invention provides conjugates comprising a short isolated peptide coupled to a sphingolipid, the peptide comprising a sequence derived from the HIV-1 gp41. The sphingolipid-peptide conjugates are suitable for treatment of infections caused by human and non-human retroviruses, especially HIV.Type: ApplicationFiled: April 3, 2013Publication date: February 12, 2015Inventors: Yechiel Shai, Avraham Ashkenazi
-
Publication number: 20150044703Abstract: Some embodiments of the present invention relate to methods and compositions for detecting the presence of cancer. In particular, methods and compositions for detecting endometrial cancer or ovarian cancer are provided.Type: ApplicationFiled: March 12, 2013Publication date: February 12, 2015Applicant: University of South AlabamaInventors: Michael A. Finan, Rodney P. Rocconi, Lewis K. Pannel
-
Publication number: 20150045283Abstract: The present invention provides novel PAR lderived cytoprotective oligopeptides or polypeptides which typically contain at least the first 4 N-terminal residues that are substantially identical to the corresponding N-terminal residues of Met1-Arg46 deleted human PAR 1 sequence. These cytoprotective oligopeptides or polypeptides are capable of activating PAR 1 and promoting PAR 1 cytoprotective signaling activities. The invention also provides engineered cells or transgenic non-human animals which harbor in their genome an altered PAR 1 gene that is resistant to cleavage at Arg41 and/or Arg46 residues. Additionally provided in the invention are methods of screening candidate compounds to identity additional cytoprotective compounds or cytoprotective proteases. The invention further provides therapeutic use or methods of employing a PAR 1 derived cytoprotective oligopeptide or polypeptide to treat conditions associated with tissue injuries or undesired apoptosis.Type: ApplicationFiled: November 7, 2012Publication date: February 12, 2015Inventors: Laurent O. Mosnier, John H. Griffin
-
Patent number: 8952127Abstract: The present invention provides for a bio-mimetic polymer capable of catalyzing CO2 into a carbonate.Type: GrantFiled: June 3, 2011Date of Patent: February 10, 2015Assignee: The Regents of the University of CaliforniaInventors: Chun-Long Chen, Ronald N. Zuckermann, James J. De Yoreo
-
Patent number: 8952129Abstract: Agonists of a non-proteolytically activated receptor can be used in methods for treating a disease or disorder in a subject. The methods comprise administering to the subject a therapeutically effective amount of an agonist, wherein the disease or disorder is scleroderma, macular degeneration, diabetic retinopathy, Huntington's disease, Parkinson's disease, closed head trauma, glaucoma, optic neuritis or allograft vasculopathy.Type: GrantFiled: March 24, 2009Date of Patent: February 10, 2015Assignee: The Board of Regents of the University of Texas SystemInventors: Darrell H. Carney, Randolph C. Steer
-
Patent number: 8951974Abstract: Provide are a peptide gel with practically sufficient mechanical strength and a self-assembling peptide capable of forming the peptide gel. The self-assembling peptide is formed of the following amino acid sequence: a1b1c1b2a2b3 db4a3b5c2b6a4 where: a1 to a4 each represent a basic amino acid residue; b1 to b6 each represent an uncharged polar amino acid residue and/or a hydrophobic amino acid residue, provided that at least five thereof each represent a hydrophobic amino acid residue; c1 and c2 each represent an acidic amino acid residue; and d represents a hydrophobic amino acid residue.Type: GrantFiled: March 26, 2014Date of Patent: February 10, 2015Assignees: Menicon Co., Ltd., National University Corporation Okayama UniversityInventors: Yusuke Nagai, Hidenori Yokoi, Koji Uesugi, Keiji Naruse
-
Publication number: 20150038676Abstract: A peptide or peptide derivative comprising: (i) WDLYFEIVW (SEQ ID NO: 1); or (ii) a variant amino acid sequence comprising one, two, three or four L-amino acid substitutions in WDLYFEIVW (SEQ ID NO: 1); or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. A peptide or peptide derivative comprising: (i) an amino acid sequence comprising imfwydcye; or (ii) a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye, wherein said peptide or peptide derivative has procoagulant activity.Type: ApplicationFiled: July 24, 2014Publication date: February 5, 2015Inventors: FRIEDRICH SCHEIFLINGER, MICHAEL DOCKAL
-
Publication number: 20150037330Abstract: Methods of treating a food allergy, allergic reactions, hypersensitivity, inflammatory responses, inflammation are provided. In one method, histamine releasing factor (HRF)/translationally controlled tumor protein (TCTP) is contacted with a compound that inhibits or reduces binding of HRF/TCTP to an immunoglobulin in order to treat the food allergy, allergic reaction, hypersensitivity, inflammatory response, or inflammation. Methods of reducing or decreasing the probability, severity, frequency, duration or preventing a subject from having an acute or chronic food allergy, allergic reaction, hypersensitivity, an inflammatory response or inflammation, are also provided.Type: ApplicationFiled: August 18, 2014Publication date: February 5, 2015Applicant: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGYInventors: Toshiaki Kawakami, Yuko Kawakami
-
Publication number: 20150038675Abstract: The purpose of the present invention is to provide: a peptide having an affinity for silicon nitride; a polynucleotide encoding the peptide; an expression vector for expressing the peptide having an affinity for silicon nitride; an expression vector for expressing a peptide fusion protein that comprises the peptide having an affinity for silicon nitride and a target protein; a transformant obtained by introducing the expression vector into a host cell; a peptide fusion protein obtained from the transformant; a silicon nitride substrate to which a peptide having an affinity for silicon nitride has been bonded; a method for immobilizing a target protein to a silicon nitride substrate; a composition for immobilizing a target protein to a silicon nitride substrate, the composition comprising a peptide having an affinity for silicon nitride; and a linker for immobilizing a target protein to a silicon nitride substrate, the linker comprising a peptide having an affinity for silicon nitride.Type: ApplicationFiled: February 12, 2013Publication date: February 5, 2015Inventors: Yoichi Kumada, Michimasa Kishimoto, Takeru Otsuka
-
Publication number: 20150038408Abstract: The present invention provides polypeptides that recognize and are strong binders to Influenza A hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection. The present invention further provides isolated nucleic acids encoding the polypeptides of the invention, recombinant expression vectors comprising the nucleic acids encoding the polypeptides of the invention operatively linked to a suitable control sequence, and recombinant host cells comprising the recombinant expression vectors of the invention. The present invention also provides antibodies that selectively bind to the polypeptides of the invention, and pharmaceutical compositions comprising one or more polypeptides according to the invention and a pharmaceutically acceptable carrier.Type: ApplicationFiled: March 12, 2013Publication date: February 5, 2015Inventors: David Baker, Timothy A. Whitehead, Sarel Fleishman
-
Publication number: 20150037823Abstract: The invention relates to the identification of a biomarker whose abundance in biological sample is changed in subjects with osteoarthritis and/or other ageing-related diseases. The biomarker has applications in the diagnosis of osteoarthritis and/or other ageing-related diseases, in determining the prognosis for an individual diagnosed with osteoarthritis and/or other ageing-related diseases, and in monitoring the efficacy of treatment for osteoarthritis and/or other ageing-related diseases.Type: ApplicationFiled: June 27, 2014Publication date: February 5, 2015Inventors: Yves Henrotin, Myriam Gharbi, Michelle Deberg, Edwin De Pauw